KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2025)

Alnylam Pharmaceuticals' Convertible Debt history spans 4 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Convertible Debt fell 1.64% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, down 1.64%, while the annual FY2025 figure was $1.0 billion, 1.64% down from the prior year.
  • Convertible Debt reached $1.0 billion in Q4 2025 per ALNY's latest filing, down from $1.0 billion in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $1.0 billion in Q3 2025 to a low of $1.0 billion in Q4 2025.
  • Average Convertible Debt over 4 years is $1.0 billion, with a median of $1.0 billion recorded in 2023.
  • The largest YoY upside for Convertible Debt was 1.62% in 2025 against a maximum downside of 1.64% in 2025.
  • A 4-year view of Convertible Debt shows it stood at $1.0 billion in 2022, then grew by 0.38% to $1.0 billion in 2023, then increased by 0.38% to $1.0 billion in 2024, then fell by 1.64% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Convertible Debt are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).